MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (1680)	6/19/2006 2:14:35 PM
From: Ward Knutson	Read Replies (2) of 1826

<<I do not know how much impact this has. Old news behind the drop from the $30s (in other words, the reason sales slowed and guidance lowered)?>> Zero impact. Aloxi is day one dosing for the prevention of acute and delayed emesis. The guidelines are simply stating that for managing delayed N&V in highly emetogenic the rec'd therapy includes the addition of an NK-1. This does NOT supplant the need for the day one 5HT-3 for acute control, and aloxi is not given in follow-up dosing in any event. The point is that follow-on oral 5HT-3 dosing is of no value for the prevention of delayed nausea and vomiting - this is especially so with highly emetogenic regimens. A fact that the data has shown all along. Aloxi, as proven by the trials, is far more effective in both delayed and acute N&V, than the other 5HT-3's. And there is never a case where an NK-1 is a replacement for the 5HT-3 due to its lack of control in the acute control.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next